Organoid technology for personalized pancreatic cancer therapy

BACKGROUND: Pancreatic ductal adenocarcinoma has the lowest survival rate among all major cancers and is the third leading cause of cancer-related mortality. The stagnant survival statistics and dismal response rates to current therapeutics highlight the need for more efficient preclinical models. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Bengtsson, Axel, Andersson, Roland, Rahm, Jonas, Ganganna, Karthik, Andersson, Bodil, Ansari, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985124/
https://www.ncbi.nlm.nih.gov/pubmed/33492660
http://dx.doi.org/10.1007/s13402-021-00585-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985124/
https://www.ncbi.nlm.nih.gov/pubmed/33492660
http://dx.doi.org/10.1007/s13402-021-00585-1

Ejemplares similares